Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a crossover trial of SCH 420814 for antipsychotic-induced extrapyramidal symptoms
2005-006048-42Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of preladenant in schizophrenia, schizoaffective disorder and extrapyramidal movement disorder (EPS) (2 arms), sponsored by Merck & Co. Started May 2006; status: completed.
02
Drugs
preladenant
03
Conditions
schizophreniaschizoaffective disorderextrapyramidal movement disorder (EPS)
Beyond the preview
Go deeper on 2005-006048-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006048-42.